Today's Rundown Biogen bullish on prospects of Alzheimer's drug aducanumab Horizon sets up shop in Bay Area at it ramps up R&D, manufacturing Azeria raises £32M to take breast cancer drug into humans Mount Sinai researchers uncover new genetic drivers of Parkinson's disease EuroBiotech Report—Bayer's phase 3 success, U.K. trial investment, EU fund, MorphoSys and Tissium FiercePharmaAsia—Novartis' Shanghai R&D revamp; BeiGene’s Imbruvica rival; Shionogi’s antibiotic Chutes & Ladders—Yumanity snags ex-Shire exec Robertson as CMO Featured Story | | | Friday, November 22, 2019 Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite it failing an interim analysis in phase 3. |
|
|---|
|
Top Stories Friday, November 22, 2019 Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco. It plans to explore the biotech hub for new partnerships and add jobs spanning the areas of bioanalysis, clinical research, pharmacology, manufacturing and business development. Friday, November 22, 2019 Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic. The money will fund work on small molecule inhibitors of FOXA1, a pioneer factor involved in tumor development. Friday, November 22, 2019 Researchers at the Mount Sinai Icahn School of Medicine used a statistical method called multiscale gene network analysis to identify the gene STMN2 as a key regulator of Parkinson’s disease. They believe the discovery could aid the development of targeted therapies for Parkinson's. Thursday, November 21, 2019 In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. Friday, November 22, 2019 Novartis is shutting down its Shanghai R&D site's discovery function in favor of drug development. BeiGene nabbed a landmark FDA nod for Brukinsa, a challenger to J&J and AbbVie's Imbruvica. Shionogi's antibiotic Fetroja won FDA approval with a mortality warning. And more. Friday, November 22, 2019 Yumanity nabs ex-Shire exec Robertson as CMO; DiMartino new R&D chief at Kronos; Longtime Arrowhead exec Given steps down. Enrollment Showcase Resources Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC See why visionaries outsource the design and management of the infrastructure allowing their scientists to innovate. Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2020 January 14, 2020 | The Fairmont Hotel | San Francisco, CA 4th Annual Gene Therapy for Rare Disorders March 30 – April 2, 2020 | Boston, MA A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 